What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

December 8, 2025Blood

Chemotherapy-free treatment for children and adolescents with newly diagnosed acute promyelocytic leukemia (APL): Results of the prospective ICC-APL-02 study.

View Full Paper

Ask AI

Bookmark

Authors

PMPietro MerliChildren's Hospital of Philadelphia MCMaria Giuseppina CefaloBambino Gesù Children's Hospital BBBarbara BuldiniUniversity of Padua

Discussion

Member takes

Implication

Prospective study demonstrates high event-free survival in pediatric patients with newly diagnosed acute promyelocytic leukemia, indicating effectiveness of ATRA, arsenic trioxide, and gemtuzumab ozog

Key Points

Event-free survival is high at 96.4% among pediatric patients with acute promyelocytic leukemia, demonstrating the effectiveness of the treatment.
In a multicenter prospective study involving 110 patients, all except one achieved hematological complete remission after induction.
Treatment protocol included ATRA and arsenic trioxide, with gemtuzumab ozogamicin used for high-risk patients through induction and consolidation phases.
This pediatric trial highlights the potential of non-chemotherapy options to manage de novo acute promyelocytic leukemia effectively.

Cite This Study

Merli et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1d1 https://doi.org/10.1182/blood-2025-880

View Full Paper

Ask AI

Bookmark

Chemotherapy-free treatment for children and adolescents with newly diagnosed acute promyelocytic leukemia (APL): Results of the prospective ICC-APL-02 study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Chemotherapy-free treatment for children and adolescents with newly diagnosed acute promyelocytic leukemia (APL): Results of the prospective ICC-APL-02 study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider